Dr Francisco Rivero Crespo F.Rivero-Crespo@hull.ac.uk
Reader in Biomedical Science
Dr Francisco Rivero Crespo F.Rivero-Crespo@hull.ac.uk
Reader in Biomedical Science
Dr Simon Calaminus S.Calaminus@hull.ac.uk
Professor Steve Archibald S.J.Archibald@hull.ac.uk
Professor in Molecular Imaging
Platelet activation and thrombus formation play key roles in the pathogenesis of ischaemic cardiovascular diseases, one of the major causes of death in the UK. Many antiplatelet agents have been developed to manage these conditions; however, they are associated with a high risk of bleeding. This justifies the need to find new targets for antiplatelet drugs that effectively inhibit thrombosis while maintaining haemostasis. Actomyosin-driven contraction is a crucial process for effective platelet adhesion, spreading and aggregation at the sites of vascular damage and for thrombus formation and consolidation. The myosin light chain phosphatase (MLCP) is a key modulator of this process. We have gathered data demonstrating a novel interaction of the targeting subunit of MLCP with the regulatory subunits of protein kinase A (PKA), one of the principal inhibitors of platelet function. Our pilot data show that disrupting this interaction prevents platelets from adhering, spreading and aggregating. Based on our pilot data we propose the development and functional testing of peptides that disrupt the interaction of MLCP and PKA as a novel therapeutic approach for the prevention and management of cardiovascular conditions associated to thrombus formation.
Status | Project Live |
---|---|
Funder(s) | British Heart Foundation |
Value | £110,680.00 |
Project Dates | Jul 3, 2023 - Jul 2, 2026 |
ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging Feb 1, 2017 - Jan 31, 2020
Cardiovascular diseases (CVD) including heart attacks and strokes constitute the leading cause of mortality in the UK. The pathology underlying CVD is called atherothrombosis and is a complex, multi-cellular-inflammatory disorder. Central to this is...
Read More about ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging.
TRANSFORM: Reducing Inequalities in Cancer Outcomes in Yorkshire: Realising our potential for innovation in Diagnosis, Patient Management, Survivorship and Palliative Care Research Sep 1, 2017 - Dec 31, 2026
The death rate is higher in Yorkshire than the rest of England resulting in about 200 extra deaths each year of which more than half are in Hull. There are other significant cancer outcome inequalities between different groups; for example poorer pe...
Read More about TRANSFORM: Reducing Inequalities in Cancer Outcomes in Yorkshire: Realising our potential for innovation in Diagnosis, Patient Management, Survivorship and Palliative Care Research.
Translational Research in the Molecular Imaging Research Centre Aug 1, 2016 - Jul 31, 2018
New technology to improve capability for clinical radiopharmaceutical production Jan 1, 2019 - Feb 28, 2022
Medical imaging techniques rely on radioactive atoms that don't last for a long time and so methods need to be developed to handle them on hospital sites or close by. Essentially this is drug factory near to the patient as the material is decaying al...
Read More about New technology to improve capability for clinical radiopharmaceutical production.
Positron Emission Tomography research Mar 1, 2016 - Feb 28, 2017
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
Apache License Version 2.0 (http://www.apache.org/licenses/)
Apache License Version 2.0 (http://www.apache.org/licenses/)
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search